Intellia Therapeutics Inc NTLA:NASDAQ

Last Price$113.13NASDAQ Closing Price as of 1:00PM ET 11/26/21

Today's Change-2.39(2.07%)
Bid (Size)$111.26 (5)
Ask (Size)$115.00 (2)
Day Low / High$111.01 - 117.95
Volume494.5 K
 

View Biotechnology IndustryPeer Comparison as of 11/26/2021

 

Intellia Therapeutics Inc ( NASDAQ )

Price: $113.13
Change: -2.39 (2.07%)
Volume: 494.5 K
1:00PM ET 11/26/2021
 
 

Neurocrine Biosciences Inc ( NASDAQ )

Price: $86.98
Change: -0.88 (1.00%)
Volume: 510.4 K
1:00PM ET 11/26/2021
 
 

N/A ( N/A )

Price: N/A
Change: N/A N/A
Volume: N/A
N/A
 
 

Natera Inc ( NASDAQ )

Price: $94.66
Change: -1.44 (1.50%)
Volume: 719.7 K
1:00PM ET 11/26/2021
 
 

Mirati Therapeutics Inc ( NASDAQ )

Price: $136.76
Change: -4.44 (3.14%)
Volume: 324.9 K
1:00PM ET 11/26/2021
 

Read more news Recent News

Intellia Therapeutics Expands Phase 1 Study of NTLA-2001 to Patients With Transthyretin Amyloidosis With Cardiomyopathy
9:32AM ET 11/22/2021 MT Newswires

Intellia Therapeutics (NTLA) said Monday that it's expanding its phase 1 study of NTLA-2001 to include adults with transthyretin amyloidosis with...

--HC Wainwright Adjusts Intellia Therapeutics' Price Target to $182 from $171, Keeps Buy Rating
11:33AM ET 11/05/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--Oppenheimer Adjusts Intellia Therapeutics PT to $145 From $160, Maintains Perform Rating
10:46AM ET 11/05/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--Wedbush Adjusts Price Target for Intellia Therapeutics to $137 From $130, Maintains Neutral Rating
2:59PM ET 11/04/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Company Profile

Business DescriptionIntellia Therapeutics, Inc. is a clinical stage genome editing company, which engages in the development of curative therapeutics using the CRISPR/Cas9 system. Its CRISPR/Cas9 system transforms medicine by both producing therapeutics that permanently edit and/or correct disease-associated genes in the human body with a single treatment course, and creates engineered cells that can treat oncological and immunological diseases. The company was founded by Andrew May, Luciano Marraffini, Rodolphe Barrangou, Nessan Bermingham, Rachel Haurwitz, Erik Sontheimer, Jennifer Doudna, and Derrick Rossi in May 2014 and is headquartered in Cambridge, MA. View company web site for more details
Address40 Erie Street
Cambridge, Massachusetts 02139
Phone+1.857.285.6200
Number of Employees211
Recent SEC Filing11/26/2021SC 13G/A
President, Chief Executive Officer & DirectorJohn M. Leonard
Executive VP, Chief Financial & Accounting OfficerGlenn Goddard
Chief Scientific Officer & Executive VPLaura Sepp-Lorenzino
Chief Medical Officer & Executive Vice PresidentDavid Lebwohl

Company Highlights

Price Open$112.18
Previous Close$115.52
52 Week Range$35.61 - 202.73
Market Capitalization$8.3 B
Shares Outstanding73.5 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement02/24/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$3.36
Beta vs. S&P 500N/A
Revenue$30.4 M
Net Profit Margin-854.10%
Return on Equity-34.22%

Analyst Ratings as of 11/04/2021

Buy
14
Overweight
1
Hold
3
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset